TGN continues to expand its IP portfolio in the area of cancer drug discovery and delivery technologies. It has recently obtained a US patent for ovarian cancer for drug development using non-human primate model. It has acquired license for two key technologies from the University of or South Florida, Tampa. The current patents allow the development of products and their marketing for cancer biology research and research on drug discovery.
Chitosan-Graphene Biosensors and Methods for Their Use. Mohapatra, S et al. US patent No: 9,091,640 Issue Date: July 28, 2016
Three-dimensional Fibrous Scaffolds for cell culture. Mohapatra et al. United States Patent: 9,618,501. Issue Date: 04/11/2017.
Three-dimensional Fibrous Scaffolds for cell culture. Mohapatra et al. United States Patent: 9,624,473. Issue Date: 04/18/2017.
Method of inducing cancer, US Patent 8,502,015, W. Xu, August 6, 2013